Gene · 64761
Papers1,639
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 1,639
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Vesicular translocation of PARP-1 to cytoplasm causes ADP-ribosylation and disassembly of vimentin filaments during microglia activation induced by LPS. | Front Cell Neurosci | 2024 | 38590714 | PubTator, text mining | PubMed |
| Proceedings of the CIMAGO Congress - Environment, Genetics and Oncobiology in the 21st Century - Challenges and Opportunities. | Medicine (Baltimore) | 2024 | 38579039 | PubTator, text mining | PubMed |
| DePARylation is critical for S phase progression and cell survival. | Elife | 2024 | 38578205 | PubTator, text mining | PubMed |
| Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts. | bioRxiv | 2024 | 38559022 | PubTator, text mining | PubMed |
| pADP-ribosylation regulates the cytoplasmic localization, cleavage, and pro-apoptotic function of HuR. | Life Sci Alliance | 2024 | 38538092 | PubTator, text mining | PubMed |
| High-throughput screening assay for PARP-HPF1 interaction inhibitors to affect DNA damage repair. | Sci Rep | 2024 | 38365924 | PubTator, text mining | PubMed |
| Deciphering the immunological and prognostic features of hepatocellular carcinoma through ADP-ribosylation-related genes analysis and identify potential therapeutic target ARFIP2. | Cell Signal | 2024 | 38302034 | PubTator, text mining | PubMed |
| Methylation of histone H3 lysine 36 is a barrier for therapeutic interventions of head and neck squamous cell carcinoma. | Genes Dev | 2024 | 38286657 | PubTator, text mining | PubMed |
| Mutation of a highly conserved isoleucine residue in loop 2 of several β-coronavirus macrodomains indicates that enhanced ADP-ribose binding is detrimental to infection. | bioRxiv | 2024 | 38260573 | PubTator, text mining | PubMed |
| Exploring DNA Damage and Repair Mechanisms: A Review with Computational Insights. | BioTech (Basel) | 2024 | 38247733 | PubTator, text mining | PubMed |
| Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors. | Sci Adv | 2024 | 38241363 | PubTator, text mining | PubMed |
| Radiosensitization of Osteosarcoma Cells Using the PARP Inhibitor Olaparib Combined with X-rays or Carbon Ions. | J Cancer | 2024 | 38213724 | PubTator, text mining | PubMed |
| An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer. | Eur J Med Chem | 2024 | 38194775 | PubTator, text mining | PubMed |
| ANP32B promotes colorectal cancer cell progression and reduces cell sensitivity to PRAP1 inhibitor through up-regulating HPF1. | Heliyon | 2024 | 38192816 | PubTator, text mining | PubMed |
| Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer. | Cell Death Dis | 2024 | 38182579 | PubTator, text mining | PubMed |
| Isolation and detection of DNA-protein crosslinks in mammalian cells. | Nucleic Acids Res | 2024 | 38084926 | PubTator, text mining | PubMed |
| PRAME induces genomic instability in uveal melanoma. | Oncogene | 2024 | 38030788 | PubTator, text mining | PubMed |
| Decoding m6A mRNA methylation by reader proteins in liver diseases. | Genes Dis | 2024 | 37692496 | PubTator, text mining | PubMed |
| The Role of the AT-Rich Interaction Domain 1A Gene (ARID1A) in Human Carcinogenesis. | Genes (Basel) | 2023 | 38275587 | PubTator, text mining | PubMed |
| The Role of the Toll-like Receptor 2 and the cGAS-STING Pathways in Breast Cancer: Friends or Foes? | Int J Mol Sci | 2023 | 38203626 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64761/papers?page=7